Haoxi Health Technology Ltd

HAO

Market cap $3.71M

Overview Fund Activity

1.28 USD

-0.04

3.03%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

1.20

-0.08

6.25%

1 day

-3.03%

5 days

6.67%

1 month

7.56%

3 months

5.79%

6 months

-22.89%

Year to date

-65.5%

1 year

-98.56%

5 years

-99.03%

10 years

-99.03%

About: Haoxi Health Technology Ltd is an online marketing solution provider in China, with an advertiser client base mainly in the healthcare industry. Haoxi has been rooted in the field of local online effect marketing for many years, serving customers in various industries at home and abroad, and its main business is the medical industry. It generates its revenue by providing one-stop online marketing solutions, in particular online short video marketing solutions, to advertisers through its media partners. The company provides customized marketing solutions by planning, producing, placing, and optimizing online ads, especially online short video ads, to help its advertisers acquire, convert, and retain ultimate consumers on various online media platforms.

Employees: 30

Communication Services Advertising Agencies

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

4.84% less ownership

Funds ownership: 5.71% [Q1] → 0.87% (-4.84%) [Q2]

50% less funds holding

Funds holding: 6 [Q1] → 3 (-3) [Q2]

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

84% less capital invested

Capital invested by funds: $154K [Q1] → $24.7K (-$129K) [Q2]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

See Fund Rankings

Financial journalist opinion

Haoxi Health Technology Limited Launches Customized Livestreaming Agency Strategy

BEIJING, April 21, 2025 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, announced that Beijing Haoxi Digital Technology Co., Ltd. (“Haoxi Beijing”), a wholly-owned subsidiary of the Company, has launched its customized livestreaming agency strategy and is progressing partnership discussions on personalized livestreaming agency services with several long-term clients of medical aesthetics, marking a new strategic step in the Company's business development roadmap.

Haoxi Health Technology Limited Launches Customized Livestreaming Agency Strategy

Haoxi Health Technology Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

BEIJING, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced that it received a formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company's Class A ordinary shares, par value US$0.0025 each (the “Ordinary Shares”) to maintain a minimum bid price of $1.00 per share.

Haoxi Health Technology Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Haoxi Health Technology Limited Announces 1-for-25 Reverse Share Split

BEIJING, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced that it has resolved to effect a reverse share split of the Company's ordinary shares, with the split ratio set at 1-for-25 (the “Reverse Share Split”). The Reverse Share Split was approved by the Company's shareholders at an annual general meeting of shareholders held on January 10, 2025. The Company's Class A ordinary shares will begin trading on an adjusted basis on the Nasdaq Capital Market, reflecting the Reverse Share Split, when the market opens on January 27, 2025, under the existing ticker symbol “HAO.” The new CUSIP number for the Company's Class A ordinary shares will be G4290F118.

Haoxi Health Technology Limited Announces 1-for-25 Reverse Share Split

Haoxi Health Technology Limited Awarded a RMB30 Milllion Framework Contract to Provide Digital Advertising Services for Tengyuan Media Advertising Co., Ltd.

BEIJING, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced the Company's wholly owned subsidiary Beijing Haoxi Digital Technology Co., Ltd. (“Beijing Haoxi”) was awarded a Recharge Service Framework Contract (the “Contract”) to provide comprehensive digital advertising services with a budget of RMB30 million for Tengyuan Media Advertising Co., Ltd. (“Tengyuan") and its clients.

Haoxi Health Technology Limited Awarded a RMB30 Milllion Framework Contract to Provide Digital Advertising Services for Tengyuan Media Advertising Co., Ltd.

Haoxi Health Technology Limited Reports Financial Results for Fiscal Year Ended June 30, 2024

BEIJING, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today reported its financial results for the fiscal year ended June 30, 2024.

Haoxi Health Technology Limited Reports Financial Results for Fiscal Year Ended June 30, 2024

Haoxi Health Technology Limited Announces Preliminary Unaudited FY24 Financial Results with projected 72% Revenue Growth

BEIJING, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced preliminary unaudited financial results for the fiscal year ended June 30, 2024 (“FY24”).

Haoxi Health Technology Limited Announces Preliminary Unaudited FY24 Financial Results with projected 72% Revenue Growth

Haoxi Health Technology Limited and Global Mofy AI Ltd Announce Strategic Partnership to Innovate AI Marketing Solutions

BEIJING, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced a strategic partnership with an AI platform, Gauss Intelligence (Beijing) Technology Co., Ltd., a subsidiary of Global Mofy AI Ltd (Nasdaq: GMM). This collaboration aims to leverage the advanced capabilities of Gausspeed, a cutting-edge generative AI platform, alongside HAO's extensive application scenarios to deliver transformative AI marketing solutions.

Haoxi Health Technology Limited and Global Mofy AI Ltd Announce Strategic Partnership to Innovate AI Marketing Solutions

Haoxi Health Technology Limited Announces the Closing of a $12 Million Underwritten Follow-on Public Offering

BEIJING, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced that it closed its previously announced underwritten follow-on offering of 4,000,000 units (each a “Unit,” and collectively, the “Units”) at a public offering price of $3.00 per Unit (the “Offering”). Each Unit consists of (i) one share of Class A Ordinary Share, par value $0.0001 per share (the “Class A Ordinary Share”) (or one pre-funded warrant to purchase one Class A Ordinary Share (the “Pre-Funded Warrant”)), (ii) one Series A warrant to purchase one Class A Ordinary Share (the “Series A Warrant”) initially, but five Class A Ordinary Shares on and after the Series B Exercise Date, and (iii) one Series B warrant to purchase four of Class A Ordinary Shares on and after the sixteenth (16th) calendar day (the “Series B Exercise Date”) following the closing of the Offering (the "Series B Warrant”, together with the Series A Warrant, the “Warrants”). The Units have no stand-alone rights and therefore are not certificated or issued as stand-alone securities. The Class A Ordinary Shares and related Warrants are issued separately in the Offering. The Company received aggregate gross proceeds of $12,000,000 from the Offering, before deducting underwriting discounts and other offering expenses, excluding the exercise of any Warrants.

Haoxi Health Technology Limited Announces the Closing of a $12 Million Underwritten Follow-on Public Offering

Haoxi Health Technology Limited Announces Pricing of a $12 Million Underwritten Follow-on Public Offering

BEIJING, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced the pricing of its underwritten follow-on public offering (the "Offering") of 4,000,000 units (each a “Unit,” and collectively, the “Units”) at an offering price of $3.00 per Unit (the “Public Offering Price”) for total gross proceeds of $12,000,000, before deducting underwriting discounts and other offering expenses. Each Unit consists of (i) one share of Class A Ordinary Share, par value $0.0001 per share (the “Class A Ordinary Share”) (or one pre-funded warrant to purchase one Class A Ordinary Share (the “Pre-Funded Warrant”)), (ii) one Series A warrant to purchase one Class A Ordinary Share (the “Series A Warrant”) (subject to certain adjustments therein), and (iii) one Series B warrant to purchase such number of Class A Ordinary Share described in the prospectus of the Offering (the "Series B Warrant”, together with the Series A Warrant, the “Warrants”). The Warrants will have a term of 5 years from the closing date of the Offering (the “Closing Date”). The Series A Warrant is exercisable immediately upon issuance, or the Closing Date. The Series B Warrant is exercisable at any time on or after the sixteenth (16th) calendar day from the Closing Date (the “Series B Exercise Date”). The Series A Warrants have an initial exercise price of $3.00 per Class A Ordinary Share. On the Series B Exercise Date, the exercise price of the Series A Warrant will be adjusted to $0.60 and the maximum number of Class A Ordinary Shares issuable upon exercise of the Series A Warrants will be adjusted to 20,000,000 shares. The exercise price of the Series B Warrants is $0.0001 per Class A Ordinary Share. The maximum number of shares issuable upon exercise of the Series B Warrants will be 16,000,000 shares. The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The Class A Ordinary Shares, the Pre-Funded Warrants, and related Warrants are immediately separable and will be issued separately in the Offering.

Haoxi Health Technology Limited Announces Pricing of a $12 Million Underwritten Follow-on Public Offering

Haoxi Health Technology Limited Facilitates International Humanitarian Aid Efforts Amid Global Challenges

BEIJING--(BUSINESS WIRE)--HAO has established a dedicated service team, collaborating closely with medical aid organizations to assess frontline medical supply requirements.

Haoxi Health Technology Limited Facilitates International Humanitarian Aid Efforts Amid Global Challenges

See News Rankings

Charts implemented using Lightweight Charts™